<DOC>
	<DOCNO>NCT00160862</DOCNO>
	<brief_summary>The primary objective determine effect single oral dose 250 mg SLV 317 substance P-induced venodilation hand vein healthy male volunteer compare placebo .</brief_summary>
	<brief_title>NK-1 Antagonism SLV317 Humans</brief_title>
	<detailed_description>This double-blind , placebo-controlled , oral single dose cross-over study . 18 healthy male volunteer receive 250 mg SLV 317 placebo randomise order minimum wash-out period one week two administration . Pharmacodynamic assessment perform 4.25 hour post-dose use dorsal hand vein compliance technique . After obtain venoconstriction via infusion phenylephrine , substance P co-infused intermittently induce venodilation . Substance P infusion separate interval 45 minute order prevent well-known occurrence tolerance . Venous blood sample pharmacokinetic evaluation perform 24 hour post-dose . Safety assess measure ECG , pulse rate , blood pressure , haematology , blood chemistry , urinalysis , monitor adverse event .</detailed_description>
	<criteria>Male nonsmoking volunteer , age : 1845 , body mass index ( BMI ) range 1926 ( kg/m2 ) , inclusive Good health determine medical history , physical examination , electrocardiogram , serum/urine biochemistry haematology A lying blood pressure rest 5 minute 100 150 mmHg ( systolic ) 5090 mmHg ( diastolic ) A lying heart rate ( ECG ) rest 5 minute 45 100 beats/min . Able willing give write informed consent Known condition cause endothelial dysfunction ( e.g . diabetes , hyperlipidaemia , smoking , arterial hypertension , hyperhomocysteinaemia ) Evidence cardiovascular , gastrointestinal/hepatic , neurologic/psychiatric , respiratory , urogenital , haematologic/immunologic , HEENT ( head , ears , eye , nose , throat ) , dermatologic/connective tissue , musculoskeletal , metabolic/nutritional , drug hypersensitivity , allergy , endocrine , major surgery , relevant disease reveal history , physical examination , laboratory assessment may interfere absorption , distribution , metabolism elimination drug constitute risk factor take study medication A known history epilepsy relatives epilepsy Use drug ( prescribe nonprescribed ) within last 2 week exception paracetamol 48 hour start study Any acute chronic illness Participation clinical trial blood donation within 2 month study Drug and/or alcohol abuse use alcoholic beverage within 48 hour prior study positive drug alcohol test Use tobacco nicotine form cotinine urinary level 500 ng/ml Carriers Hepatitis B surface antigen ( HBsAg ) carrier Hepatitis C HIV virus A body temperature 37.5 Â°C</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>